Viracta Therapeutics, Inc. Share Price Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.847 USD | -95.45% | 0.00% | 0.00% |
Sales 2024 * | - | Sales 2025 * | 2.33M 186M | Capitalization | 32.53M 2.59B |
---|---|---|---|---|---|
Net income 2024 * | -62M -4.94B | Net income 2025 * | -86M -6.85B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 13.9 x |
P/E ratio 2024 * |
-0.71
x | P/E ratio 2025 * |
-0.74
x | Employees | 40 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.08% |
Latest transcript on Viracta Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 62 | 18/09/22 |
Melody Burcar
DFI | Director of Finance/CFO | 41 | 31/08/22 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 30/09/07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 31/01/21 |
Barry Simon
BRD | Director/Board Member | 69 | 02/03/21 |
1st Jan change | Capi. | |
---|---|---|
+2.39% | 42.75B | |
+47.70% | 41.61B | |
+11.98% | 41.34B | |
-8.83% | 26.59B | |
+6.81% | 25.49B | |
-22.86% | 18.12B | |
+30.68% | 12.24B | |
-2.12% | 11.76B | |
+9.11% | 11B |